Three-species platform optimizes the discovery of diverse fully human antibodies

Ligand Pharmaceuticals’ cutting-edge OmniAb antibody platform leverages genetically engineered rats, mice and chickens to provide the industry’s widest epitope coverage with broad freedom to operate.

Go to the profile of Ligand Pharmaceuticals
May 23, 2019
1
0
Page of
Go to the profile of Ligand Pharmaceuticals

Ligand Pharmaceuticals

Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue.

No comments yet.